Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2023 Jul 5;28(7):e542-e553.
doi: 10.1093/oncolo/oyad064.

Patient Understanding of Oncology Clinical Trial Endpoints in Direct-to-Consumer Television Advertising

Helen W Sullivan  1 , Amie C O'Donoghue  1 , Vanessa Boudewyns  2 , Ryan S Paquin  2 , Kate Ferriola-Bruckenstein  3
Affiliations
Randomized Controlled Trial

Patient Understanding of Oncology Clinical Trial Endpoints in Direct-to-Consumer Television Advertising

Helen W Sullivan et al. Oncologist. .

Abstract

Background: This study examined how people interpret overall survival (OS), overall response rate (ORR), and progression-free survival (PFS) endpoints in the context of direct-to-consumer television ads. Although there is little research on this topic, initial evidence suggests that people can misinterpret these endpoints. We hypothesized that understanding of ORR and PFS would be improved by adding a disclosure ("We currently do not know if [Drug] helps patients live longer") to ORR and PFS claims.

Methods: We conducted 2 online studies with US adults examining television ads for fictional prescription drugs indicated to treat lung cancer (N = 385) or multiple myeloma (N = 406). The ads included claims about OS, ORR with and without a disclosure, or PFS with and without a disclosure. In each experiment, we randomized participants to view 1 of 5 versions of a television ad. After viewing the ad twice, participants completed a questionnaire that measured understanding, perceptions, and other outcomes.

Results: In both studies, participants correctly differentiated between OS, ORR, and PFS via open-ended responses; however, participants in the PFS conditions (versus ORR conditions) were more likely to make incorrect inferences about OS. Supporting the hypothesis, adding a disclosure made expectations around living longer and quality-of-life improvements more accurate.

Conclusion: Disclosures could help reduce the extent to which people misinterpret endpoints like ORR and PFS. More research is needed to establish best-practice recommendations for using disclosures to improve patient understanding of drug efficacy without changing their perception of the drug in unintended ways.

Keywords: disclosures; endpoints; oncology; pharmaceutical promotion; prescription drugs; regulatory science.

PubMed Disclaimer

Conflict of interest statement

The authors indicated no financial relationships.

Figures

Figure 1.
Figure 1.
CONSORT diagram.
See this image and copyright information in PMC

References

    1. von Itzstein M, Railey E, Smith M, et al. Patient familiarity with, understanding of, and preferences for clinical trial endpoints and terminology. Cancer. 2020;126(8):1605-1613. - PMC - PubMed
    1. Sullivan HW, Aikin KJ, Squiers LB.. Quantitative information on oncology prescription drug websites. J Cancer Educ. 2018;33(2):371-374. - PMC - PubMed
    1. McCaffrey K. Oncology Marketing Goes Prime Time: Pharma Brands Move to DTC Advertising to Capture Market Share . MM&M/Haymarket Media, Inc. Published 2017. Accessed January 21, 2021. http://media.mmm-online.com/documents/306/mm_m_oncology_marketing_ebook_...
    1. iSpot.tv. Rx: Cancer TV Commercials. iSpot.tv Web site. Published 2022. Accessed November 28, 2022. https://www.ispot.tv/browse/7k.bv/pharmaceutical-and-medical/rx-cancer
    1. Gray SW, Abel GA.. Update on direct-to-consumer marketing in oncology. J Oncol Pract. 2012;8:124-127. https://doi.org/ 10.1200/JOP.2011.000513 - DOI - PMC - PubMed

Publication types